US equities |
MU $1,088.00 ▲+0.00% SNDK $1,692.42 ▲+0.00% NVDA $237.47 ▲+0.00% INTC $113.12 ▲+0.00% PLTR $194.12 ▲+0.00% AMD $645.86 ▲+0.00% SPCX $167.60 ▲+0.00% MSTR $153.37 ▲+0.00%
FinancialContent

Pacira BioSciences, Inc. - Common Stock (NQ:PCRX)

25.20 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pacira BioSciences, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Pacira BioSciences Receives FDA 510k Clearance for New iovera° SmartTip to Manage Chronic Low Back Pain via Long-lasting Medial Branch Nerve Block
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
News headline image
Lost Money on Pacira BioSciences, Inc.(PCRX)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Via ACCESSWIRE
News headline image
Decoding 6 Analyst Evaluations For Pacira BioSciences ↗
 
Via Benzinga
News headline image
Evaluating Pacira BioSciences: Insights From 8 Financial Analysts ↗
 
Via Benzinga
News headline image
Insights into Pacira BioSciences's Upcoming Earnings ↗
 
Via Benzinga
News headline image
Expert Ratings For Pacira BioSciences ↗
 
Via Benzinga
News headline image
Shareholder Rights Advocates at Levi & Korsinsky Investigate Pacira BioSciences, Inc. (PCRX) Regarding Possible Securities Fraud Violations
Via ACCESSWIRE
News headline image
Pacira BioSciences, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Pacira BioSciences, Inc. (PCRX)
Via ACCESSWIRE
News headline image
Investors seeking growth at a reasonable cost should explore NASDAQ:PCRX. ↗
Investors should take note ofPACIRA BIOSCIENCES INC (NASDAQ:PCRX), a growth stock that remains attractively priced. 
Via Chartmill
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Awarded New U.S. Patent Covering EXPAREL Composition
From Pacira BioSciences
Via GlobeNewswire
News headline image
Where Pacira BioSciences Stands With Analysts ↗
 
Via Benzinga
News headline image
Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
-- Poster to be presented at ACR Convergence annual meeting -- 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Third Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
Seasoned Executive Brings More Than 25 Years of Global Financial and Operational Biopharmaceutical Leadership Experience 
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Pacira BioSciences
Via GlobeNewswire
News headline image
Pain Management-Focused Pacira BioSciences Loses Patent Fight For Key Drug, JP Morgan Analyst Downgrades On Unclear Path ↗
Pacira BioSciences faces a significant setback as the U.S. District Court invalidates its key patent on Exparel, leading to a 40% stock drop. Exparel, crucial to Pacira's revenue, is now vulnerable,... 
Via Benzinga
Topics Intellectual Property
News headline image
JetBlue Airways, B. Riley Financial, Hawaiian Electric And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
From Pacira BioSciences
Via GlobeNewswire
News headline image
NASDAQ:PCRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
In a market where value is scarce, PACIRA BIOSCIENCES INC (NASDAQ:PCRX) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
PCRX Stock Earnings: Pacira BioSciences Beats EPS, Beats Revenue for Q2 2024 ↗
PCRX stock results show that Pacira BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Pacira BioSciences Reports Second Quarter 2024 Financial Results
From Pacira BioSciences
Via GlobeNewswire
News headline image
3 Biotech Stocks to Buy on the Dip: July 2024 ↗
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >